You have 9 free searches left this month | for more free features.

Relapsed / Refractory CLL

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
Aug 19, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

CLL/SLL Trial in Worldwide (Epcoritamab, Venetoclax)

Not yet recruiting
  • CLL/SLL
  • Antwerpen, Belgium
  • +23 more
Mar 28, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

Chronic Lymphocytic Leukemia, Richter Syndrome Trial in United States (Duvelisib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Miami, Florida
  • +6 more
Jan 6, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib (Arm A)
  • Acalabrutinib (Arm B)
  • Bethesda, Maryland
    Research Site
Jan 3, 2023

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)

Terminated
  • Chronic Lymphocytic Leukemia(CLL)
  • Small Lymphocytic Lymphoma
  • Hackensack, New Jersey
    Hackensack University Medical Center
Jun 24, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +5 more
  • (no location specified)
Jul 21, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial

Active, not recruiting
  • Contiguous Stage II Small Lymphocytic Lymphoma
  • +11 more
  • MOR00208
  • +2 more
  • Columbus, Ohio
    The Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

Recruiting
  • Follicular B-cell Non-Hodgkin's Lymphoma
  • +7 more
  • MB-106
  • Orange, California
  • +3 more
Nov 1, 2022

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
Nov 1, 2021

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphoid Leukemia
  • Dresden, Germany
  • +16 more
Nov 8, 2022

Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)

Completed
  • Chronic Lymphocytic Leukemia
  • BNC105P
  • Ibrutinib
  • Lebanon, New Hampshire
    Dartmouth-Hitchcock Medical Center
Jan 3, 2023

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

AML Trial in Hangzhou (CLL1 CAR-T)

Not yet recruiting
  • AML
  • CLL1 CAR-T
  • Hangzhou, China
    The First Affiliated Hospital, Zhejiang University
Jul 17, 2022

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 13, 2022

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

Chronic Lymphocytic Leukemia Trial in Washington, Hackensack (Venetoclax, Rituximab, Rituximab/Hyaluronidase Human)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Washington, District of Columbia
  • +1 more
Mar 14, 2022

B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Cyclophosphamide injection
  • +2 more
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Jan 18, 2023